Governor Patrick Signs Pharmacy Reforms into Law to Enhance Industry Oversight and Protect Patients by Massachusetts. Governor.
Commonwealth of Massachusetts Executive Department 
Office of Governor Deval L. Patrick 
Press Release 
Contact: Heather Nichols, Rachael Neff, Juli Hanscom – 617-725-4025; 
Alec Loftus (HHS) – 617-573-1612 
                        Follow us on Twitter – View our Photos – Watch our Videos  
 
GOVERNOR PATRICK SIGNS PHARMACY REFORMS 
INTO LAW TO ENHANCE INDUSTRY OVERSIGHT AND 
PROTECT PATIENTS 
BOSTON – Thursday, July 10, 2014 – Governor Deval Patrick today signed into law 
comprehensive compounding pharmacy reform legislation, which allows Massachusetts 
to better protect patients inside and outside the Commonwealth’s borders. The Act 
includes new licensing, labeling, education and oversight requirements, in addition to 
new penalties and fines for pharmacies who do not comply with the law. 
“Every patient deserves to know that the medication they are taking is safe,” said 
Governor Patrick. “This law gives Massachusetts the strength and flexibility to better 
oversee compounding pharmacy practice and protect patients.” 
The Governor signed H. 4235, “An Act Relative to Pharmacy Practice in the 
Commonwealth,” at a ceremony at the State House following unanimous passage of the 
Act by both the Massachusetts Senate and House of Representatives.  
“The tragic meningitis outbreak that was traced to a compounding pharmacy in 
Framingham seriously injured an alarming number of people all across the country, and 
it was imperative that we took action to prevent a similar situation from happening again 
in the future,” said Senate President Therese Murray. “This legislation strengthens our 
policies regarding the oversight, regulation and quality of our compounding pharmacies 
and these were necessary steps we needed to take to ensure the health of our 
residents.” 
“This legislation ensures that we are doing all we can to guarantee the highest 
standards of safety, oversight and transparency for compounding pharmacies,” said 
House Speaker Robert A. DeLeo. “The distribution of contaminated drugs that occurred 
in 2012 was an egregious tragedy, but I’m proud of our strong and comprehensive 
response. Massachusetts prides itself on being a hub of health care and medical 
excellence. It is my hope that these reforms will set a national standard so that no 
individual is again affected by this kind of negligence.” 
Today’s bill signing directs the Board of Pharmacy to: 
 Update its membership with enhanced expertise in critical areas of pharmacy 
practice;  
 Create new state licensing for sterile, complex non-sterile, hospital and out-of-
state pharmacies;  
 Authorize new penalties and fines for pharmacies who do not comply with the 
law;  
 Require robust product labeling and reporting of adverse drug events;  
 Set new continuing education rules;  
 Eliminate the “gray area” between manufacturing and compounding; and 
 Improve transparency in the industry as a whole, increasing patient education 
and confidence in received medications. 
 
“We are committed to fully implementing these measures to ensure patients are 
receiving the highest-quality and safest products,” said Department of Public Health 
Commissioner Cheryl Bartlett, RN. “This law will also improve transparency in the 
industry, increase patient education and assure the public that their medications are 
safe.” 
Governor Patrick filed comprehensive pharmacy reform legislation in January 2013, 
following the fungal meningitis outbreak linked to New England Compounding Center. 
Thursday’s signing builds upon strong steps the Patrick Administration has already 
taken, in partnership with the Legislature, to increase oversight of the industry, including 
allocating additional resources to the Board of Pharmacy for additional inspectors and 
improved pharmacy oversight. Additionally, Governor Patrick convened a Special 
Commission on the Oversight of Compounding Pharmacies to analyze needs and gaps 
in the industry and recommend changes. The signed Act advances many of these 
critical recommendations.  
 
“This process has been long in the making,” said Senator John F. Keenan. “We wanted 
to ensure our consideration of this complex topic was thorough, and that our outcome 
would be a comprehensive policy that can be emulated across the country. With this 
legislation, we will go from the state where an unregulated pharmacy compounded a 
substance that killed dozens of people and caused more than 700 to deal with serious 
illness, to the state which provides patients with the best safety standards in the 
country.” 
 
“I am pleased that this legislation incorporates a number of the changes to the industry 
my investigation as Chair of the Senate Post Audit and Oversight Committee 
recommended,” said Senator Mark Montigny. “Legislation can only go so far, we must 
continue to be vigilant in the monitoring of this industry and those special interests 
surrounding it if we are to be truly successful in protecting the public.”     
“This legislation updates the state laws under which compounding pharmacies operate 
in a meaningful way to better prevent an event like the meningitis outbreak of 2012 from 
ever occurring in the future,” said Senator Richard T. Moore. “Where Massachusetts 
leads the nation in research, innovation and health care, it is essential that we also 
ensure patient safety for those who utilize compounded drugs that are manufactured 
within the Commonwealth.” 
 
“This legislation clearly defines the boundaries of safe and appropriate compounding 
and applies strict standards to all pharmacies producing or shipping compounding drugs 
in Massachusetts,” said Representative Jeffrey Sánchez. “Massachusetts will now have 
among the most rigorous standards for compounding in the nation, but these are 
achievable standards that balance patient safety with patient access to medically 
necessary drugs.” 
 
“Having begun work on this legislation as a member of the Governor’s Special 
Commission, I am pleased we were able to come to agreement on a piece of legislation 
which will clarify and strengthen the regulations around sterile and complex non-sterile 
compounding practices in the Commonwealth,” said Representative David T. Vieira. 
“This legislation will also broaden the representation on the Board of Pharmacy to make 
sure all stakeholders have a seat at the table.” 
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